Cargando…
Inosine Pranobex Significantly Decreased the Case-Fatality Rate among PCR Positive Elderly with SARS-CoV-2 at Three Nursing Homes in the Czech Republic
During the COVID-19 pandemic, the elderly population has been disproportionately affected, especially those in nursing homes (NH). Inosine pranobex (IP) has been previously demonstrated to be effective in treating acute viral respiratory infections. In three NH experiencing the SARS-CoV-2 virus epid...
Autores principales: | Beran, Jiří, Špajdel, Marian, Katzerová, Věra, Holoušová, Alena, Malyš, Jan, Finger Rousková, Jana, Slíva, Jiří |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766462/ https://www.ncbi.nlm.nih.gov/pubmed/33339426 http://dx.doi.org/10.3390/pathogens9121055 |
Ejemplares similares
-
Correction: Beran et al. Inosine Pranobex Significantly Decreased the Case-Fatality Rate among PCR Positive Elderly with SARS-CoV-2 at Three Nursing Homes in the Czech Republic. Pathogens 2020, 9, 1055
por: Beran, Jirí, et al.
Publicado: (2021) -
Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course
por: Beran, Jiří, et al.
Publicado: (2021) -
Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study
por: Beran, Jiří, et al.
Publicado: (2016) -
Genotoxicity and Mutagenicity of Inosine Pranobex
por: Tobólska, Sylwia, et al.
Publicado: (2018) -
Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases
por: Sliva, Jiri, et al.
Publicado: (2019)